Manolete FY26 slides: record forward book offsets revenue dip

Manolete reported FY26 realized revenue of £27.9 million, down 6% YoY, but gross profit rose 8% to £10.4 million and the forward book hit a record £67 million, up 37%. Management introduced medium-term targets for £42 million in revenue, a 12% PBT margin, and £37 million in gross cash receipts, supported by a higher-value case mix and 1,027 new referrals. Near-term profits were weak due to a £1.8 million bad debt provision, but the strong pipeline and improved case economics point to FY27 growth.

Analysis

The key read-through is that this is a capacity-constrained compounder transitioning from “recovering earnings” to “balance-sheet-funded growth,” which changes the stock’s economic sensitivity. The record pipeline matters more than the headline PBT because the mix shift toward larger claims should mechanically lift both duration-adjusted revenue and realized margins, while the added legal headcount is a leading indicator of FY27/FY28 conversion rather than a cost overhang. In other words, the market is likely still pricing Manolete as a lumpy, one-off recovery story when it is increasingly behaving like a scaled origination platform with recurring case flow.

The second-order winner is likely HSBC rather than Manolete’s equity holders in the near term: a larger forward book and rising case investments increase working-capital needs, so the business remains dependent on revolving credit and collections discipline until debtor aging improves further. The real operational swing factor is not case wins but monetization latency; if collections continue to normalize, the company can self-fund growth and re-rate on cash conversion, but if debtor delays persist, the higher-quality pipeline simply stretches the cash cycle and delays equity value realization. That makes the next 2-3 quarters more about cash receipts and overdue debtors than about headline revenue.

Contrarianly, the market may be underestimating how much optionality sits in the cartel book and in the implied value of the current forward book. If the medium-case mix continues to migrate upward, the company can hit the stated £150k average case target faster than consensus likely models, which would force a material upward revision to FY27/FY28 margins and NAV. The stock remains a classic rerating candidate, but only if investors stop anchoring on current earnings and start marking the platform on forward book quality and cash conversion.

Key Decisions for Investors

• Long MANO on a 6-12 month horizon: asymmetry favors upside if forward-book conversion stays intact and collections normalize; target a rerating toward book value or above, with downside anchored by tangible NAV.
• Use pullbacks to add, not chase: the next 1-2 quarters may remain noisy due to debtor timing, so entry should be staged rather than all at once; the catalyst is the FY27 conversion rate, not next quarter EPS.
• Pair trade: long MANO / short a slower-growth UK small-cap financials basket — the case-mix upgrade and operational leverage should outperform balance-sheet-heavy, low-growth peers if cash receipts improve.
• Buy MANO call spreads out 6-9 months if liquid options are available: limited premium outlay for exposure to a rerating on forward-book growth, with defined risk if collections slip.
• Monitor HSBC covenant sensitivity and debtor aging as hard risk markers; if overdue debtors re-accelerate for two consecutive periods, reduce exposure because equity value will remain trapped in receivables rather than monetized profit.